Search results
Structural basis of tolvaptan binding to the vasopressin V2 receptor - Acta Pharmacologica Sinica
Nature· 5 days agoThe vasopressin V2 receptor (V2R) is a validated therapeutic target for autosomal dominant polycystic kidney disease (ADPKD), with tolvaptan being the first FDA-approved antagonist. Herein, ...